Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the company's regulatory submissions and the risks associated with them [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Allarity's securities between May 17, 2022, and July 19, 2024, and encourages them to contact the Schall Law Firm before November 12, 2024 [1]. - The complaint alleges that Allarity and its executives made false and misleading statements regarding the Dovitinib NDA and Dovitinib-DRP PMA, which increased the company's exposure to regulatory scrutiny [2]. - The company is accused of downplaying the likelihood of enforcement actions after an investigation was announced, leading to materially misleading public statements throughout the class period [2]. Group 2: Investor Participation - Investors are invited to join the class action to recover their losses, with the Schall Law Firm specializing in securities class action lawsuits and shareholder rights litigation [3].

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk’s U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarit ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities between May 17, 2022, and July 19, 2024, of the upcoming lead plaintiff deadline on November 12, 2024, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Allarity securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2]. - To serve as lead plaintiff, individuals must file a motion with the court by November 12, 2024 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Allarity and its former officers made false statements regarding the regulatory prospects of Dovitinib, a drug candidate for renal cell carcinoma [4]. - It is claimed that the defendants engaged in improper conduct related to the drug's new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [4]. - The lawsuit asserts that Allarity downplayed the likelihood of enforcement actions following an investigation into these matters, resulting in materially false and misleading public statements [4].

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

LOS ANGELES, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). If you suffered a loss on your Allarity investments or would like to inquire about potentiall ...

SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024. Allarity is a clinical-stage biopharmaceutical company that develops oncology therapeutics using drug-specific companion diagnostics generated by its Drug Response Predictor technology. For more information, submit a form, emai ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024. SO WHAT: If you purchased Allarity securities during ...

NEWTOWN, Pa., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the recent filing of a securities fraud class action on behalf of purchasers of Allarity Therapeutics, Inc. (NASDAQ: ALLR) common stock between May 17, 2022, and July 19, 2024, inclusive (the “Class Period”). A copy of the Complaint can be found HERE. Investors who purchased Allarity stock may move the U.S. District Court for the Southern District of New York to appoint them as lead plaintiff, n ...

NEW YORK, Sept. 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024.So what: If you purchased Allarity securities during the Class ...